The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
AIMS: We performed a network meta-analysis of randomized controlled trials (RCTs) in patients with primary hypercholesterolaemia to compare the impact of proprotein convertase subtilisin-kexin type 9 serine protease (PCSK9) inhibitors with placebo and ezetimibe on lipid levels and outcomes. METHODS AND RESULTS: MEDLINE/PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched for RCTs assessing PCSK9 inhibitors vs. other therapies in patients with primary hypercholesterolaemia. Network meta-analysis with both a frequentist approach and a Bayesian framework was performed to directly and indirectly compare PCSK9 inhibition on lipid levels with ezetimibe and placebo. Odds ratios with 95% confidence intervals (OR [95% CIs]) were generated with random-effects models to compare outcomes. Our meta-analysis included 17 RCTs with 13 083 patients that were randomized to PCSK9 inhibitors (n = 8250), placebo (n = 3957), ezetimibe (n = 846), or PCSK9 inhibitors and ezetimibe (n = 30). The mean age was 59 ± 10, 52% were male, 34% had coronary artery disease, 51% had hypertension, 19% had diabetes mellitus, baseline LDL of 122 ± 36 mg/dL, total cholesterol of 199 ± 39 mg/dL, and HDL of 51 ± 14 mg/dL. inhibitors significantly reduced LDL cholesterol by 57% relative to placebo (P < 0.001) and 36.1% relative to ezetimibe (P < 0.001). Proprotein convertase subtilisin-kexin type 9 serine protease inhibitors reduced the incidence of all-cause mortality [OR 0.43 (95% CI 0.22-0.82), P = 0.01] but was associated with an increased incidence of neurocognitive adverse events [OR 2.34 (95% CI 1.11-4.93), I(2) = 4%, P = 0.02] when compared with placebo. CONCLUSION: Proprotein convertase subtilisin-kexin type 9 serine protease inhibition significantly improved lipid profiles and reduced the incidence of all-cause mortality compared with placebo but had a higher rate of neurocognitive adverse events. Thus, PCSK9 inhibitor therapy may serve as an alternative for patients with statin intolerance and for those who do not respond to other lipid reduction therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the combined analysis of both studies indicated an increased occurrence of neurocognitive side effects in patients treated with PCSK9 inhibitors (83).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [83]
In the citing paper
“Indeed, the occurrence of undesirable side effects has been questioned in terms of cognitive function [196,197] and negative impact on the immune system regulation that could lead to different inflammatory diseases [104].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [196]
In the citing paper
“In clinical trials, bile acid sequestrants have contributed greatly to the demonstration of the efficacy of LDL-C lowering in reducing CV events in hypercholesterolaemic people, with a benefit proportional to the degree of LDL-C lowering.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [277]
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 2×
“All included studies had a low risk of bias as assessed by the Cochrane Collaboration tool for assessing risk of bias(8) (see Supplementary material online, Table S1) and all studies were deemed High Quality by the GRADE system.(9) Baseline study characteristics can be found in Table 1.”
MethodCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · cited 1×
“provided with statin therapy resulted in a significant reduction in CV events.(5) The results of IMPROVE-IT appear to support the find-”
Result(2008) · Cited by 3,790
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181 · cited 1×
“Proprotein convertase subtilisin-kexin type 9 serine protease (PCSK9) plays an important role in regulating LDL cholesterol and sequence variants in the PCSK9 gene are associated with significant reductions in not only LDL cholesterol but also lower risk of coronary artery disease (CAD).(6,7) Given the improvement in…”
BackgroundEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“These findings appear to be largely driven by the findings of the ODYSSEY LONG TERM and OSLER 2 trials.(38,40) When limiting the analysis to studies with follow-up of 6 months or greater, there were significantly fewer CV events in the PCSK9 inhibitor group than in patients randomized to placebo (OR 0.”
Result
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“In some studies, an increase of patient-reported neurocognitive effects has been described.(293) However, the EBBINGHAUS trial,(231) which was specifically designed to detect neurocognitive function changes, was reassuring, as were the safety reports in both the FOURIER and ODYSSEY trials.”
ResultGiugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Cognitive function in a randomized trial of evolocumab
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Sousa-Uva*, M., Head, S. J., Milojevic, M., Collet, J.-P., Landoni, G., Castella, M., Dunning, J., Gudbjartsson, T., Linker, N. J., Sandoval, E., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx314 · Cited by 393
Metadata
- Authors
- Lipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R.
- Affiliations
- MedStar Washington Hospital Center (US)
- Bristol Royal Infirmary (GB)
- Corresponding author
- Waksman, Ron
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-17
- Volume
- 37
- Issue
- 6
- Pages
- 536-545
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2175943040
- Cited by
- 256
- References
- 47
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 19 · 2023: 12 · 2022: 11 · 2021: 16 · 2020: 15 · 2019: 23 · 2018: 32 · 2017: 56 · 2016: 55
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9 inhibitors, primary hypercholesterolemia, ezetimibe, LDL cholesterol lowering, all-cause mortality, serum lipids, statins, cardiovascular outcomes, hypertriglyceridemia, dyslipidemia, drug efficacy comparison, coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia treatment
- MeSH terms
- Network Meta-Analysis, Proprotein Convertase 9, PCSK9 Inhibitors, Anticholesteremic Agents, Humans, Hypercholesterolemia, Cholesterol, LDL, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. https://app.cochat.ai/papers/10.1093/eurheartj/ehv563
- The paper
- Lipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R. (2016). The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.